The Phase I/II LIGHTHOUSE trial is assessing the safety and tolerability of the gene therapy in male subjects.

Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that the U.S. Food and Drug ...

The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

DURHAM, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent ...

Atsena Therapeutics Inc. is the business for which the check was intended. Investigators reported they spoke to the business owner, who said they were unaware they were missing a check.

The LIGHTHOUSE study is a Phase I/II, open-label, dose-escalation and dose-expansion clinical trial evaluating the safety and tolerability of ATSN-201 in male patients ages six and older with a ...

Atsena Therapeutics (“Atsena”) is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases.

For more information about the preclinical study and how works, visit . Atsena Therapeutics (“Atsena”) is a clinical-stage gene therapy company developing best-in-class treatments for the ...

Atsena Therapeutics ("Atsena”) is a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases. The company's ...